Cue Biopharma (NASDAQ:CUE) Issues Quarterly Earnings Results

Cue Biopharma (NASDAQ:CUE) announced its quarterly earnings data on Friday. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45), FiscalAI reports. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $3.00 million. Cue Biopharma had a negative net margin of 59.65% and a negative return on equity of 98.30%.

Cue Biopharma Trading Up 10.0%

Cue Biopharma stock traded up $3.12 during trading hours on Friday, hitting $34.20. 157,074 shares of the stock traded hands, compared to its average volume of 195,652. Cue Biopharma has a one year low of $4.97 and a one year high of $45.50. The company has a market cap of $143.64 million, a PE ratio of -6.12 and a beta of 2.47. The firm’s 50-day moving average price is $29.50 and its two-hundred day moving average price is $147.28.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Weiss Ratings upgraded shares of Cue Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, May 18th. Wall Street Zen lowered Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cue Biopharma currently has a consensus rating of “Sell”.

Insiders Place Their Bets

In related news, CEO Shao-Lee Lin sold 18,258 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $28.62, for a total value of $522,543.96. Following the sale, the chief executive officer directly owned 705,995 shares of the company’s stock, valued at $20,205,576.90. This represents a 2.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 14.56% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. grew its holdings in Cue Biopharma by 730.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after purchasing an additional 73,000 shares during the period. Squarepoint Ops LLC purchased a new position in shares of Cue Biopharma during the third quarter valued at approximately $62,000. Stifel Financial Corp boosted its position in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Boothbay Fund Management LLC boosted its position in shares of Cue Biopharma by 15.3% in the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after purchasing an additional 93,333 shares in the last quarter. 35.04% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Cue Biopharma

Here are the key news stories impacting Cue Biopharma this week:

• Positive Sentiment: Second-quarter revenue was $7.88 million, well above the consensus estimate of $3.00 million, providing a favorable revenue surprise for the clinical-stage biotechnology company. Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Neutral Sentiment: Cue Biopharma reported recent business highlights alongside its quarterly results, but the available report does not provide enough detail to assess their potential impact on its clinical pipeline or valuation. The company remains focused on developing targeted immunotherapies for cancer and infectious diseases.
• Negative Sentiment: The company posted a quarterly loss of $24.14 per share, substantially worse than the expected loss of $1.69 per share. Cue Biopharma also reported a negative net margin of 59.65% and negative return on equity of 98.30%, underscoring its continuing unprofitability and clinical-development risk. Cue Biopharma earnings report
• Negative Sentiment: CEO Shao-Lee Lin sold 18,258 shares for approximately $522,544 on August 13, following a 40,000-share sale worth $1.08 million on August 12. Both transactions were reportedly made to cover tax-withholding obligations from vested equity awards, which reduces the negative signal, but the combined insider selling may still weigh on investor sentiment. Cue Biopharma CEO stock sale
• Negative Sentiment: Wall Street Zen downgraded CUE from “Buy” to “Hold.” MarketBeat also reported a consensus “Sell” rating from the tracked analyst coverage, reinforcing concerns about the company’s losses and biotechnology execution risk. Wall Street Zen downgrades Cue Biopharma

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.